Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for ...